Pepsinogens to Distinguish Patients With Gastric Intestinal Metaplasia and Helicobacter pylori Infection Among Populations at Risk for Gastric Cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The objectives of this study were to investigate the serum pepsinogen test for the prediction of OLGIM (Operative Link on Gastric Intestinal Metaplasia Assessment) stages in first-degree relatives (FDR-GC) of patients with gastric cancer (GC) and autoimmune chronic atrophic gastritis (ACAG). METHODS: In 67 consecutive patients with ACAG, 82 FDR-GC, and 53 controls (CTRL) without gastric disease (confirmed by biopsy), serum levels of pepsinogen 1 (PG1), pepsinogen 2 (PG2), G17, and the PG1/2 ratio were assessed by enzyme-linked immunosorbent assay kit. All ACAG patients had positive antiparietal cell antibody levels, estimated by indirect immunofluorescence. Biopsies taken in duplicate from the antrum, corpus, and fundus were stained with Giemsa for Helicobacter pylori detection. Endoscopic detection of metaplasia was confirmed by histological diagnosis. Histological classification of OLGIM stages was applied by using the criteria of severity and topography of intestinal metaplasia (IM). RESULTS: The highest discrimination capacity for distinguishing ACAG from other groups of patients was the gastrin G17 test. The lowest mean for PG1 and PG2 serum levels was found in ACAG. In multivariate analysis by age, PG1 and PG1/PG2 were independent prognostic factors for metaplasia, and PG2 also for the presence of a histological H. pylori infection. The serum PG1 level was significantly lower in individuals with IM at OLGIM stage >2 than in those with IM at OLGIM stage <2, resulting in a useful method for the prediction of OLGIM stage. With the inclusion of patient age at diagnosis in the prediction of ≥2 vs. 0-1 OLGIM stages, the receiver operating characteristic (ROC) curve at 47.9 ng/ml PG1 level reached a significant area under the curve (AUC) value (0.978, P<0.001). We also observed a slight difference in PG2 serum levels between histological H. pylori-positive and H. pylori-negative subjects (ROC AUC: 0.599). CONCLUSIONS: This study demonstrated an important increase in gastrin G17 serum level in autoimmune gastritis. PG1 serum level corrected by patient age can be used in the management of patients at risk for GC with a high predicted probability of having an OLGIM stage ≥2. Using a cutoff of 47.9 ng/ml, PG1 testing in FDR-GC and ACAG patients had a sensitivity of 95.83% and a specificity of 93.37. Although these results could be validated in a prospective study, the known importance of higher OLGIM stages in increasing the risk of GC development supports the rationale of proposing PG1 algorithm as a diagnostic tool for the selection of high-risk FDR-GC and ACAG patients at high-risk stages for subsequent detailed endoscopic examination to detect dysplasia and asymptomatic GC. In addition, serum PG1 and PG2 levels could stratify patients based on both H. pylori infection and OLGIM risk in consideration of the increased acknowledge regarding the role of H. pylori in the progression of gastritis to GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gender Gap in Autoimmunity: Task Force on Gender, Multiple Sclerosis and Autoimmunity
Whitacre, C. C., Reingold, S. C., O'Looney, P. A., Blankenhorn, E., Brinley, F., Collier, E., Duquette, P., Fox, H., Giesser, B., Gilmore, W., et al. (1999) · Science · doi:10.1126/science.283.5406.1277 · Cited by 851
In Vitro Expansion of Human Gastric Epithelial Stem Cells and Their Responses to Bacterial Infection
Bartfeld, S., Bayram, T., van de Wetering, M., Huch, M., Begthel, H., Kujala, P., Vries, R., Peters, P. J., & Clevers, H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.042 · Cited by 820
Capelle, L. G., de Vries, A. C., Haringsma, J., Ter Borg, F., de Vries, R. A., Bruno, M. J., van Dekken, H., Meijer, J., van Grieken, N. C. T., & Kuipers, E. J. (2010) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2009.12.029 · Cited by 608 · cited 1×
“” For the development of the IM staging system OLGIM, atrophic gastritis in the OLGA was replaced by IM, and a combination of the IM scores resulted in the OLGIM staging score, as reported elsewhere.(28)”
ResultGastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study
RUGGE, M., DE BONI, M., PENNELLI, G., DE BONA, M., GIACOMELLI, L., FASSAN, M., BASSO, D., PLEBANI, M., & GRAHAM, D. Y. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04277.x · Cited by 280
Cited by
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J.-M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327745 · Cited by 1,533
Malfertheiner, P., Camargo, M. C., El-Omar, E., Liou, J.-M., Peek, R., Schulz, C., Smith, S. I., & Suerbaum, S. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00431-8 · Cited by 1,191
Lahner, E., Zagari, R. M., Zullo, A., Di Sabatino, A., Meggio, A., Cesaro, P., Lenti, M. V., Annibale, B., & Corazza, G. R. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.09.016 · Cited by 187
Yue, H., Shan, L., & Bin, L. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0812-3 · Cited by 183
A current clinical overview of atrophic gastritis
Annibale, B., Esposito, G., & Lahner, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1718491 · Cited by 84
“Another pitfall of these meta-analyses [97,102] is that”
Background
Metadata
- Authors
- De Re, V., Orzes, E., Canzonieri, V., Maiero, S., Fornasarig, M., Alessandrini, L., Cervo, S., Steffan, A., Zanette, G., Mazzon, C., De Paoli, P., & Cannizzaro, R.
- Venue
- Clinical and Translational Gastroenterology
- Published
- 2016-07
- Volume
- 7
- Issue
- 7
- Pages
- e183
- ISSN
- 2155-384X (ISSN-L)
- OpenAlex
- W2505534345
- Cited by
- 47
- References
- 4
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.